
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 3.170 | 3.170 | 0.000 |
Shares | 96.800 | 96.800 | 0.000 |
Other | 0.030 | 0.030 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 24.002 | 18.810 |
Price to Book | 7.269 | 3.238 |
Price to Sales | 5.244 | 2.343 |
Price to Cash Flow | 19.847 | 12.765 |
Dividend Yield | 1.088 | 1.986 |
5 Years Earnings Growth | 10.736 | 10.719 |
Name | Net % | Category Average |
---|---|---|
Technology | 44.320 | 20.639 |
Healthcare | 36.710 | 12.928 |
Communication Services | 18.980 | 9.574 |
Number of long holdings: 33
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Apple | US0378331005 | 9.36 | 193.16 | -1.94% | |
Alphabet A | US02079K3059 | 8.68 | 147.67 | -2.31% | |
NVIDIA | US67066G1040 | 8.37 | 96.91 | -4.51% | |
Microsoft | US5949181045 | 7.60 | 359.12 | -2.35% | |
Meta Platforms | US30303M1027 | 5.85 | 484.66 | -3.35% | |
Eli Lilly | US5324571083 | 5.24 | 818.02 | -2.61% | |
UnitedHealth | US91324P1021 | 4.89 | 425.33 | -6.34% | |
Roche Holding Participation | CH0012032048 | 4.49 | 255.20 | -0.16% | |
Novartis | CH0012005267 | 4.04 | 91.35 | +0.79% | |
Thermo Fisher Scientific | US8835561023 | 3.78 | 421.85 | -1.32% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CIBC Nasdaq Index | 3.29B | -8.27 | 13.74 | 17.08 | ||
CIBC Nasdaq Index Premium Class | 3.29B | -8.10 | 14.67 | 18.08 | ||
CIBC US Broad Market Index | 2.31B | -5.11 | 11.60 | 11.52 | ||
CIBC US Broad Market Index Premium | 2.31B | -4.94 | 12.42 | 12.37 | ||
CIBC Managed Growth Portfolio T8 | 37.65M | -0.73 | 4.73 | 6.11 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review